Journal profile · Oncology
Clinical & Translational Oncology
ISSN 1699-048X · eISSN 1699-3055 · Springer International Publishing · SPAIN · Monthly · Founded 2000
Clinical & Translational Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.66; hybrid open access; APC about USD 4,690; median 80 days to acceptance (100 articles, last 24 months); community-reported acceptance: about 50%; 325 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical & Translational Oncology is published by Springer International Publishing and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Breast Cancer Treatment Studies, together about 20.5% of its articles. Its main subfields are Oncology and Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Mariano ProvencioPublisher website
Editorial board by country: none in mainland China; most named Spain 57, United States 2, United Kingdom 1, Italy 1, Portugal 1 (64 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine7.9%
- Lung Cancer Treatments and MutationsMedicine6.4%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology6.2%
- Lung Cancer Diagnosis and TreatmentMedicine5.5%
- Lung Cancer Research StudiesMedicine4.7%
- Colorectal Cancer Treatments and StudiesMedicine4.7%
- Ferroptosis and cancer prognosisMedicine4.7%
- Advanced Radiotherapy TechniquesPhysics and Astronomy3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.66LetPub ·
- Impact factor (publisher) 2025
- 2.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.9Publisher website ·
- CiteScore 2026-06
- 5.4LetPub ·
- SJR 2026-06
- 0.83LetPub ·
- SNIP 2026-06
- 0.75LetPub ·
- h-index
- 42LetPub ·
- h-index
- 81OpenAlex ·
- i10-index
- 2,017OpenAlex ·
- 2-year mean citedness
- 2.66OpenAlex ·
- Self-citation rate
- 3.7%LetPub ·
- Share of gold OA articles
- 24.78%LetPub ·
Volume
- Articles per year
- 302LetPub ·
- Downloads per year (publisher) 2025
- 1,300,000Publisher website ·
Articles by year OpenAlex count · 4,938 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 401 | 112 | 106 |
| 2025 | 325 | 110 | 785 |
| 2024 | 450 | 118 | 2,237 |
| 2023 | 305 | 87 | 2,737 |
| 2022 | 298 | 81 | 3,173 |
| 2021 | 217 | 59 | 3,950 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
80 daysMedian, submission to acceptance · P25–P75 45 days – 108 days
- Acceptance to online
- median 20 days (100 articles)
- Submission to online
- median 101 days
- Sample
- 100 articles with submission and acceptance dates (841 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2.2 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,690 / EUR 3,690 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Manuscript length
- ≤ 3,000 words
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted15, with length limits
- brief research articlesBrief Research Articles. Brief articles include studies whose special characteristics (e.g., small series with a limited number of observations, research with h…Length not stated
- correspondenceAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- editorialAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- full research articleAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…main text ≤ 1,500 words
- letterAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- original researchAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- original research articleAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…main text ≤ 3,000 words
- other sectionsOther sections. The journal contains other sections such as Editorials, Special Articles, or Educational Series, for which papers are solicited by the editorial…Length not stated
- perspectiveAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- research articleAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- research articlesResearch Articles. Articles report on research on the molecular and cellular bases of disease, etiology, pathophysiology, pathology, epidemiology, clinical feat…Length not stated
- reviewAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…main text ≤ 5,000 words
- review articleAs per the journal style, 6 authors + et al. should be displayed in the References list. For revised versions of the rejected manuscripts, please provide the ma…Length not stated
- review articlesReview Articles Review articles must discuss the current status of a topic from a critical perspective and then enlarge upon the subject.Length not stated
- systematic reviews and meta-analysesSystematic Reviews and Meta-Analyses. Systematic Reviews and Meta-Analyses should be submitted under the article type “Research Article”.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Conflict of interest
Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. This note should be added in a separate section before the reference list. If no conflict exists, authors should state: The authors declare that they have no conflict of interest. Back to top
Source ↗Publisher website ·- Publication ethics Ethical standards
Ethics committee approval and Declaration of Helsinki compliance required Model summary
Manuscripts submitted for publication must contain a statement to the effect that all human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. It should also be stated clearly in the text that all persons gave their informed conse…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
ORCID required for corresponding author Model summary
To find out more about publishing your work Open Access in Clinical and Translational Oncology, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer International Publishing
- Country or region
- SPAIN
- Language
- English
- Frequency
- Monthly
- Founded
- 2000
- ISSN
- 1699-048X
- Electronic ISSN
- 1699-3055
- Society / sponsor
- Federation of Spanish Oncology Societies
- Latest issue on the website
- Volume 28, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Clinical & Translational Oncology
What CAS zone is Clinical & Translational Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical & Translational Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical & Translational Oncology?
The latest impact factor listed by LetPub is 2.66; CiteScore 5.4, h-index 81.
How long does peer review take at Clinical & Translational Oncology?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 80 days (interquartile range 45–108 days); authors report an average review time of about 2.2 months; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical & Translational Oncology?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Manuscript length: ≤ 3,000 words; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical & Translational Oncology based?
Of the 64 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Spain (57), United States (2) and United Kingdom (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical & Translational Oncology?
According to LetPub and DOAJ records, Clinical & Translational Oncology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Clinical & Translational Oncology open access, and what is the APC?
Clinical & Translational Oncology is a hybrid journal. For open-access publication: APC about USD 4,690.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .